Jeff Himawan

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD.

Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas.

Essex Woodlands Health ventures Fund LP invests in startups and buyout stage industries and also focus in the areas like Pharmaceuticals, Biotechnology, Medical Devices, Health Services, Managed Care and Health Information.

Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.

Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark.

Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL.

Horizon Therapeutics USA, Inc. develops prescription drugs for mild to moderate pain relief arthritis. The company is headquartered in Northbrook, IL.

Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.

TeneoBio, Inc. operates as a biotechnology company that develops biologics, human heavy chain antibodies, as therapeutics against cancer, autoimmunity, and infectious diseases. Its products provides treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. The company was founded by Roland Buelow, on August 9, 2009 and is headquartered in Menlo Park, CA.

NexEos Diagnostics, Inc. operates as a medical diagnostics company focuses on disorders related to white blood cells. The company is headquartered in Wayne, PA.

NexEos Bio is a medical diagnostics company that aims to improve the detection, diagnosis, treatment, and management of patients with chronic, eosinophil-related inflammatory diseases. The company is based in Wayne, PA. The company's lead program is a non-invasive imaging agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis (EoE). This program has the potential to improve patients' quality of life, more rapidly diagnose their disease, and may help delay disease progression. The company was founded by Gerald Gleich, and the CEO is Theresa Mansi.

Seed-One Ventures (Seed-One) is a venture capital firm founded in 1997 by Jeff Wolf. The firm is headquartered in Durham, North Carolina.